Literature DB >> 7107002

Comparison of enzyme-linked immunosorbent assay and neutralization techniques for measurement of antibody to respiratory syncytial virus: implications for parenteral immunization with live virus vaccine.

R B Belshe, L P Van Voris, M A Mufson, E B Buynak, A A McLean, M A Hilleman.   

Abstract

The sensitivity of an enzyme-linked immunosorbent assay (ELISA) to detect low levels of antibody to respiratory syncytial (RS) virus was compared with a tube dilution neutralization test (NEUT) on sera obtained from children who received a parenteral live RS virus vaccine. Among the children who developed antibody in response to live RS virus vaccine. ELISA was as sensitive as NEUT at detecting antibody increases. Some children who did not have detectable prevaccine ELISA antibody possessed NEUT antibody; these children were generally less than 12 months old, suggesting that they had low levels of maternal antibody. Low levels of NEUT or ELISA antibody were associated with the absence of antibody increases after injection of live RS virus vaccine. The quantity of antibody stimulated by this live RS virus vaccine was small compared with that which was stimulated by naturally acquired RS virus infection. We concluded that ELISA is a satisfactory test for determining antibody to RS virus in vaccine field trials, given the understanding that low levels of preexisting antibody are not detected in some instances.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7107002      PMCID: PMC347505          DOI: 10.1128/iai.37.1.160-165.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines.

Authors:  R E Weibel; E B Buynak; A A McLean; M R Hilleman
Journal:  Pediatrics       Date:  1975-09       Impact factor: 7.124

2.  Long-term persistence of antibody following Enders' original and More attenuated live measles virus vaccine.

Authors:  E B Buynak; R E Weibel; A A Mclean; M K Hilleman
Journal:  Proc Soc Exp Biol Med       Date:  1976-12

3.  Quantitative, semiautomated, enzyme-linked immunosorbent assay for viral antibodies.

Authors:  P O Leinikki; S Passila
Journal:  J Infect Dis       Date:  1977-10       Impact factor: 5.226

4.  Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure.

Authors:  P Albrecht; F A Ennis; E J Saltzman; S Krugman
Journal:  J Pediatr       Date:  1977-11       Impact factor: 4.406

5.  A generalization of the one-sided two-sample Kolmogorov-Smirnov statistic for evaluating diagnostic tests.

Authors:  M H Gail; S B Green
Journal:  Biometrics       Date:  1976-09       Impact factor: 2.571

6.  Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex.

Authors:  R H Parrott; H W Kim; J O Arrobio; D S Hodes; B R Murphy; C D Brandt; E Camargo; R M Chanock
Journal:  Am J Epidemiol       Date:  1973-10       Impact factor: 4.897

7.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

8.  Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness.

Authors:  J Mills; J E Van Kirk; P F Wright; R M Chanock
Journal:  J Immunol       Date:  1971-07       Impact factor: 5.422

9.  Safety and antigenicity of temperature sensitive (TS) mutant respiratory syncytial virus (RSV) in infants and children.

Authors:  H W Kim; J O Arrobio; C D Brandt; P Wright; D Hodes; R M Chanock; R H Parrott
Journal:  Pediatrics       Date:  1973-07       Impact factor: 7.124

10.  Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus.

Authors:  H W Kim; J O Arrobio; G Pyles; C D Brandt; E Camargo; R M Chanock; R H Parrott
Journal:  Pediatrics       Date:  1971-11       Impact factor: 7.124

View more
  4 in total

Review 1.  Respiratory syncytial virus. Brief review.

Authors:  E J Stott; G Taylor
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

2.  Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.

Authors:  T Tao; M H Skiadopoulos; F Davoodi; J M Riggs; P L Collins; B R Murphy
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  Age related IgG subclass response to respiratory syncytial virus fusion protein in infected infants.

Authors:  P J Watt; M Zardis; P R Lambden
Journal:  Clin Exp Immunol       Date:  1986-06       Impact factor: 4.330

4.  Simplified enzyme-linked immunosorbent assay for specific antibodies to respiratory syncytial virus.

Authors:  L Vaur; H Agut; A Garbarg-Chenon; G Prud'Homme de Saint-Maur; J C Nicolas; F Bricout
Journal:  J Clin Microbiol       Date:  1986-10       Impact factor: 5.948

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.